599-P: Automated Insulin Delivery Systems and Physical Activity—Management and Outcomes

Introduction: Physical activity (PA), along with insulin adjustments and food intake for its purpose, can cause dysglycemia for people with type 1 diabetes (PWT1D), acting as a major barrier to activity. It is unclear if automated insulin delivery (AID) systems improve this situation. Methods: Observational study in real-life conditions to assess time in, below or above range (TIR, TBR 70mg/dl, TAR 180 mg/dl) and glucose variability (CV%) during PA, 1-h post-, 4-h post-PA compared to non-PA periods with continuous glucose monitors. Participants also completed a PA log for 6 weeks including PA type (continuous, intermittent or resistance) and duration. Data were analyzed using a mixed model with Bonferroni correction for post-hoc comparisons. Results: We enrolled 22 PWT1D using AID (8 males, age: 48.7 ± 13.2 years, A1c: 6.7 ± 0.5%). Participants recorded a total of 339 PA sessions (mean 15 ± 13 5 - 64; 251 continuous, 59 intermittent, 29 resistance) lasting 60.9 ± 55.6 min (10 - 430 min). We found no significant effect of PA type on TIR, TBR, TAR or CV during, 1-h post or 4-h post PA. TBR as well as TAR during, 1-h and 4-h PA were comparable to non-PA periods. CV was higher in non-PA periods. All values for TBR, TAR and CV remained within optimal recommended ranges (Table). Conclusion: PWT1D using AID successfully manage PA. Respective roles of AID algorithm and adaptive behaviors need to be investigated on a larger sample size. Disclosure J. Molveau: None. C.L. Russon: None. V. Boudreau: None. E. Nguyen: None. E. Heyman: None. J.E. Yardley: Speaker's Bureau; Dexcom, Inc. Research Support; LifeScan Diabetes Institute. R.P.R. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète. Funding Diabetes Canada (OG-3-21-5586-RR)